RecruitingNCT05549635

Database and Biobank of Patients With Hypersensitivity Pneumonitis

Pulmonary Fibrosis Biobank - Hypersensitivity Pneumonitis

Sponsor

Nils Hoyer

Enrollment

50 participants

Start Date

Sep 18, 2022

Study Type

OBSERVATIONAL

Conditions

Hypersensitivity Pneumonitis

Summary

Sub-study of the main Pulmonary Fibrosis Biomarker (PFBIO) cohort (NCT02755441), recruiting patients with an MDT-diagnosis of hypersensitivity pneumonitis (HP). Patients are included for the collection of blood samples and regular clinical data. The database and biobank will be available for studies of HP, and can be directly compared to the main PFBIO cohort, which has recruited patients with Idiopathic pulmonary Fibrosis (IPF) since 2016. Biomarkers will be assessed as diagnostic and prognostic. Further subtyping of HP, based on blood markers (including precipitins) will also be possible with the PFBIO-HP project.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is building a database and biobank (a collection of biological samples) from patients diagnosed with hypersensitivity pneumonitis (HP) — a lung disease caused by an immune reaction to inhaled substances like mold, bird droppings, or certain chemicals. By collecting clinical data and samples from patients, researchers hope to better understand the disease and improve how it is diagnosed and treated. You may be eligible if: - You are 18 years of age or older - You have been diagnosed with hypersensitivity pneumonitis by a multidisciplinary team (MDT) according to current international guidelines - You are able to provide informed consent You may NOT be eligible if: - You are unable to sign an informed consent form Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.